Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 4/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | CDK4 | P11802 | 2/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.41 |
| ▸ | CDK9 | P50750 | 2/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 2/20 | 0.40 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 4/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2230864 | 0.92 | MKNK1 (0.43) | CDK2MKNK1MKNK2GSK3BCDK4 | |
| SCHEMBL2228842 | 0.91 | MKNK1 (0.46) | CDK2MKNK1MKNK2GSK3BCDK4 | |
| SCHEMBL2227078 | 0.91 | CDK2 (0.45) | CDK2KCNH2MKNK1MKNK2GSK3B | |
| SCHEMBL2231152 | 0.90 | CDK2 (0.47) | CDK2KCNH2ACVR1MKNK1MKNK2 | |
| SCHEMBL2228005 | 0.89 | GSK3B (0.49) | CDK2MKNK1MKNK2GSK3BCDK4 | |
| SCHEMBL2226906 | 0.88 | MKNK1 (0.51) | CDK2KCNH2ACVR1MKNK1MKNK2 | |
| SCHEMBL2229775 | 0.88 | MKNK1 (0.47) | CDK2KCNH2MKNK1MKNK2GSK3B | |
| SCHEMBL2228336 | 0.87 | GSK3B (0.45) | CDK2KCNH2ACVR1MKNK1MKNK2 | |
| SCHEMBL2227901 | 0.87 | CDK2 (0.57) | CDK2KCNH2ACVR1MKNK1MKNK2 | |
| SCHEMBL2227667 | 0.87 | CDK2 (0.42) | CDK2KCNH2ACVR1MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183975-A1 | NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY | GOTO YASUHIRO | 2011-07-28 | — | — | US | claimed |
| US-20110183975-A1 | NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY | GOTO YASUHIRO | 2011-07-28 | — | — | US | disclosed |
| US-20110183975-A1 | NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY | GOTO YASUHIRO | 2011-07-28 | — | — | US | disclosed |
| US-20110183975-A1 | NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY | GOTO YASUHIRO | 2011-07-28 | — | — | US | disclosed |
| WO-2010042337-A1 | NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010042337-A1 | NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183975-A1 | NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY | BRIX1, REL, CNKSR1 | CDK2 381/4885KCNH2 757/4885ACVR1 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.